Table 1.
Clinicopathologic characteristics of TCGA-CRC cohort (N = 592) and GSE39582 cohort (N = 566), according to TIM level.
| TCGA-CRC cohort N = 592 | High-TIM N = 292 (49.3%) | Low-TIM N = 300 (50.7%) | p-Value | GSE39582 N = 566 | High-TIM N = 306 (54.1%) | Low-TIM N = 260 (45.9%) | p-Value | |
|---|---|---|---|---|---|---|---|---|
| Age at diagnosis [yrs] | ||||||||
| Median (Q1; Q3) | 68 (58; 76)a | 68 (57; 77)a | 67 (58; 75) | 0.57b | 68 (59; 76)d | 69 (58; 77) | 68 (60; 75)d | 0.72b |
| Min–max | 31–90 | 33–90 | 31–90 | 22–97 | 24–97 | 22–96 | ||
| Sex | ||||||||
| Male | 311 (52.5%) | 146 (50.0%) | 165 (55.0%) | 0.17c | 310 (54.8%) | 158 (51.6%) | 152 (58.5%) | 0.11c |
| Female | 279 (47.1%) | 144 (49.3%) | 135 (45.0%) | 256 (45.2%) | 148 (48.4%) | 108 (41.5%) | ||
| NA | 2 (0.3%) | 2 (0.7%) | 0 | – | – | – | ||
| Stage | ||||||||
| 0 | – | – | – | 4 (0.7%) | 1 (0.3%) | 3 (1.2%) | 0.0246c | |
| I | 103 (17.4%) | 52 (17.8%) | 51 (17.0%) | 0.08c | 33 (5.8%) | 19 (6.2%) | 14 (5.4%) | |
| II | 220 (37.2%) | 119 (40.8%) | 101 (33.7%) | 264 (46.6%) | 158 (51.6%) | 106 (40.8%) | ||
| III | 170 (28.7%) | 80 (27.4%) | 90 (30.0%) | 205 (36.2%) | 104 (34.0%) | 101 (38.8%) | ||
| IV | 85 (14.4%) | 32 (11.0%) | 53 (17.7%) | 60 (10.6%) | 24 (7.8%) | 36 (13.8%) | ||
| NA | 14 (2.4%) | 9 (3.1%) | 5 (1.7%) | – | – | – | ||
| Pathological lymph node status | ||||||||
| N0 | 340 (57.4%) | 182 (62.3%) | 158 (52.7%) | 0.0241c | 302 (53.4%) | 179 (58.5%) | 123 (47.3%) | 0.0208c |
| N+ | 249 (42.1%) | 108 (37.0%) | 141 (47.0%) | 244 (43.1%) | 119 (38.9%) | 125 (48.1%) | ||
| NX/NA | 3 (0.5%) | 2 (0.7%) | 1 (0.3%) | 20 (3.5%) | 8 (2.6%) | 12 (4.6%) | ||
| Pathological M status | ||||||||
| M0 | 439 (74.2%) | 222 (76.0%) | 217 (72.3%) | 0.06c | 482 (85.2%) | 272 (88.9%) | 210 (80.8%) | 0.0263c |
| M1 | 82 (13.9%) | 31 (10.6%) | 51 (17.0%) | 61 (10.8%) | 24 (7.8%) | 37 (14.2%) | ||
| MX/NA | 71 (12.0%) | 39 (13.4%) | 32 (10.7%) | 23 (4.1%) | 10 (3.3%) | 13 (5.0%) | ||
| Microsatellite status | ||||||||
| Instable | 177 (29.9%) | 106 (36.3%) | 71 (23.7%) | 0.0015c | 75 (13.3%) | 59 (19.3%) | 16 (6.2%) | <0.0001c |
| Stable | 410 (69.3%) | 183 (62.7%) | 227 (75.7%) | 444 (78.4%) | 215 (70.3%) | 229 (88.1%) | ||
| NA | 5 (0.8%) | 3 (1.0%) | 2 (0.7%) | 47 (8.3%) | 32 (10.5%) | 15 (5.8%) | ||
| Follow-up | N = 589 | N = 289 | N = 300 | N = 562 | N = 305 | N = 257 | ||
| Deaths | 120 (20.4%) | 51 (17.6%) | 69 (23.0%) | 191 (34.0%) | 87 (28.5%) | 104 (40.5%) | ||
| Survivors | 469 (79.6%) | 238 (82.4%) | 231 (77.0%) | 371 (66.0%) | 218 (71.5%) | 153 (59.5%) | ||
| Median (Q1; Q3) [yrs] in survivors | 1.8 (1.1–3.0) | 1.8 (1.1–3.0) | 2.0 (1.1–2.9) | 0.45b | 5.3 (3.4–7.1) | 5.2 (3.4–7.3) | 5.5 (2.9–7.1) | 0.79b |
Percentages could not add up 100 due to rounding.
aThree patients with missing information on age.
bWilcoxon test.
cFisher’s exact test.
dOne patient with missing information on age.